'No govt firm under pharma dept produces cancer drugs'

Image
Press Trust of India New Delhi
Last Updated : Dec 22 2015 | 4:07 PM IST
None of the state-owned firms under the Department of Pharmaceuticals (DoP) produces any kind of cancer treatment drugs, Parliament was informed today.
"None of the Public Sector Undertakings (PSUs) under the administrative control of Department of Pharmaceuticals are manufacturing drugs needed for cancer treatment," Minister of State for Chemicals and Fertilisers Hansraj Gangaram Ahir said in a written reply to the Lok Sabha.
PSUs under DoP are: Indian Drugs & Pharmaceuticals Ltd, Hindustan Antibiotics Ltd, Rajasthan Drugs & Pharmaceuticals Ltd, Karnataka Antibiotics & Pharmaceuticals Ltd and Bengal Chemicals and Pharmaceuticals Ltd.
In reply to a separate question, Ahir said DoP is framing recruitment rules to fill the vacant technical posts.
Meanwhile, the DoP has appointed retired government personnel as consultants to advise on the technical issues on pharmaceuticals, he added.
On Uniform Code of Pharmaceutical Marketing Practices (UCPMP), Ahir said majority of the companies have favoured making the code mandatory.
"A review on the implementation of of the UCPMP was held wherein it was found that majority of the companies favoured making the UCPMP mandatory," he said.
The government had prepared UCPMP which was to be adopted voluntarily by the pharma companies for a period of six months with effect from January 1, 2015.
The code was later extended up to December 31.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 22 2015 | 4:07 PM IST

Next Story